Oncology

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Abstracts presented at the 60th American Society of Hematology Annual Meeting & Exposition looked at how monitoring minimal residual disease can help predict outcomes in acute myeloid leukemia (AML).

A recent review outlined a vast array of biomarkers that may have clinical implications on the treatment and prognosis of colorectal cancer (CRC).

This week, the top managed care news included House and Senate hearings on the cost of prescription drugs; a study finding patients with diabetes can be safely switched to cheaper insulin; and the first non-chemotherapy combination being approved for the treatment of chronic lymphocytic leukemia.

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

Reflecting on a year of breakthrough advancements in the treatment of rare, difficult to treat cancers, the American Society of Clinical Oncology (ASCO) has named “Progress in Treating Rare Cancers” as the Advance of the Year.

In this podcast, we speak with Rebecca Siegel, MPH, strategic director of surveillance information services in the Intramural Research Department at the American Cancer Society, and the lead author of the annual Cancer Statistics report that estimates the number of new cancer cases and deaths in the United States each year.

https://www.pharmacytimes.org/on-demand/mantle-cell-lymphoma-mcl-treatment-landscape-and-access-to-care

The ninth annual Trending Now in Cancer Care survey identified current and emerging trends for US cancer programs, such as the ongoing threat of drug costs and popular services progams are planning to add in the next 2 years.

The approval marks the first non-chemotherapy combination regimen for the treatment of patients with chronic lymphocytic leukemia (CLL).

https://www.pharmacytimes.org/on-demand/managed-care-considerations-in-meeting-the-complex-needs-of-patients-with-pancreatic-cancer

As patients with multiple myeloma live longer thanks to advancements in treatments, more attention is being paid to treatment-related toxicities that are becoming more relevant.

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Higher tumor mutational burden is associated with improved overall survival in patients with stage IV or metastatic disease being treated with immune checkpoint inhibitors.

Patients with multiple myeloma (MM) who have high-risk cytogenetic abnormalities typically have shorter progression-free survival (PFS) and overall survival (OS) compared with standard-risk patients. In an analysis of 2 studies, patients with high-risk MM had improved outcomes when taking carfilzomib once a week compared with a twice-weekly dose.

AJMC®TV interviews let you catch up on what’s new and important about changes in healthcare, with insights from key decision makers—from the clinician, to the health plan leader, to the regulator. When every minute in your day matters, AJMC®TV interviews keep you informed. Access the video clips at ajmc.com/interviews.

Updates from the annual ASH meeting, December 2018.

Updates from the annual ASH meeting, December 2018.

Earlier this week, the US Preventive Services Task Force (USPSTF) released a draft guidance recommendations on medications for women at an increased risk for breast cancer.

Updates from the annual ASH meeting, December 2018.

Updates from the annual ASH meeting, December 2018.

Updates from the annual ASH meeting, December 2018.

Updates from annual ASH meeting, December 2018.

Updates from the annual ASH meeting, December 2018.

Updates from the annual ASH meeting, December 2018.